Polyprenols, long-chain isoprenoid alcohols of plant origin, possess notable hepatoprotective,
antioxidant, antiviral, and immunomodulatory properties and function as metabolic precursors to
dolichols, , keyessential in for glycoprotein synthesis. Despite growing pharmaceutical interest, their
hydrophobic nature hampers bioavailability in aqueous systems. We address this challenge via patented
liposomal and nanoemulsion technologies, enhancing solubility, stability, and controlled parenteral
release. To bridge research and regulatory application, we propose three novel indices—IMMPREN,
TRANSPREN, and STERILPREN—designed to quantify immunomodulatory potential, translational
readiness, and sterilization resilience, respectively. IMMPREN evaluates immune traceability
through macrophage polarization and Receiver Operating Characteristic (ROC)-based justification;
TRANSPREN structures regulatory narratives for GRAS (Generally Recognized As Safe) and Novel
Food dossiers; STERILPREN quantifies colloidal and structural integrity post- moist-heat sterilization,
aligning with SAL Sterility Assurance level (SAL) standards. Each index enables formulation traceability,
clarity in health claims, and stratification by cytokine/cell marker response, supporting injectable and
diagnostic deployment. Collectively, our platform offers a modular, regulatory-explainable framework
for polyprenol-based therapeutics—positioning these nanofor emulations as dual-use innovations in
clinical translation and safety compliance.
